parp

(redirected from parps)
Also found in: Medical.

parp

(pɑːp)
vb (intr)
to make a honking sound like a horn
n
1. a honking sound like a horn, or an instance of this
2. the sound of flatulence, or an instance of this
Collins English Dictionary – Complete and Unabridged, 12th Edition 2014 © HarperCollins Publishers 1991, 1994, 1998, 2000, 2003, 2006, 2007, 2009, 2011, 2014
References in periodicals archive ?
"The PARP family is still a mystery and that is why we need to continue to research PARPs," Palavalli Parsons said in a statement.
MONDAY, March 26, 2018 (HealthDay News) -- Vigil immunotherapy shows good tolerability for recurrent ovarian cancer patients, and PARP 7, a poly(ADP-ribose) polymerase protein, may play a significant role in survival for ovarian cancer, according to two studies presented at the Society of Gynecologic Oncology's Annual Meeting on Women's Cancer, held from March 24 to 27 in New Orleans.
Dantzer, "The diverse roles and clinical relevance of PARPs in DNA damage repair: current state of the art," Biochemical Pharmacology, vol.
Kraus, "New insights into the molecular and cellular functions of poly(ADP-ribose) and PARPs," Nature Reviews.
Hottiger, "The diverse biological roles of mammalian PARPs, a small but powerful family of poly-ADP-ribose polymerases," Frontiers in Bioscience, vol.
The nuclear protein poly(ADP-ribose) polymerase-1 (PARP-1) is a 116 kDa protein member of PARP enzyme family comprised of three functional domains.
"Given the structural and mechanistic differences between iniparib and other PARPi, these negative results do not necessarily imply a 'class effect' and further study of TN breast cancer with other PARPs should be encouraged," said M.
PARPs are an ancient family of mainly nuclear enzymes that catalyze the covalent transfer of ADP-riboses from nicotinamide dinucleotide (NAD) to acidic residues on themselves and other protein substrates.
The team of researchers, led by Rodier and his colleague Anne-Marie Mes-Masson, discovered that EOC cells enter senescence following chemotherapy in combination with PARP inhibitors.
Shares of Clovis (CLVS) are on the rise after Evercore ISI analyst Steven Breazzano upgraded the stock to Outperform, a buy-equivalent rating, citing an attractive valuation and his belief that potential of the PARP class of cancer drugs is "too big to ignore." Clovis also saw another upgrade this morning, with RBC Capital analyst Kennen MacKay raising his rating on the shares to Outperform following the positive trend vote from the European CHMP on the company's Rubraca treatment.